collegiumpharma.com (COLL): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Collegium Pharmaceutical Inc (COLL)

Collegium Pharmaceutical management is masterfully commercializing innovations in pain therapy by effectively implementing niche products. This chart on GURU.Markets shows that the company's EV/EBITDA ratio stands at 5.08. This confirms the business's resilience despite strict DEA oversight and patent barriers. High confidence in leadership is supported by systematic portfolio diversification and operational flexibility.

COLL Collegium Pharma: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/11/2026

COLL (collegiumpharma.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Collegium Pharmaceutical Inc|COLL - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Collegium Corp|COLL - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Collegium Pharmaceutical|COLL - Company Net Assets|Market Capitalization to Book Value Ratio collegiumpharma.com|COLL - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Collegium Pharmaceutical|COLL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Collegium Pharmaceutical, Inc.|COLL - Company Debts|Debt to Book Capitalization Ratio Collegium Corp|COLL - Company Long-Term Debt|Company Short-Term Debts Collegium Pharmaceutical|Quick Ratio collegiumpharma.com
- business earnings and investment ratios data:
COLL - Annual Net Income|Projected Future Earnings Collegium Pharmaceutical|COLL - Business Payback Period|Projected Price to Earnings Collegium Pharmaceutical|COLL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Collegium Corp|COLL - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Collegium Pharmaceutical|COLL - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months collegiumpharma.com|COLL - Earnings per share trend in current year|Earnings growth forecast for next year Collegium Pharmaceutical
Summary company analytics:COLL (Collegium Pharmaceutical Inc)
Original product of Collegium Pharmaceutical, Inc.

By utilizing an asset-light model with outsourced analgesic production, Collegium Pharmaceutical (COLL) optimizes capital expenditures, making the analysis of business value relative to operating profit critical. Fluctuations in the EV/EBITDA multiple reflect the market valuation of the entire company inclusive of net debt, where a declining curve indicates undervalued assets, while an increase signals overbought conditions or a decline in cash flow generation efficiency.

Who Collegium Pharmaceutical competes with

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Cronos Corp CRON|CGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation HITI (hightideinc.com)|auroramj.com (ACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Achieve Life Sciences Inc.|SKYE (Skye Bioscience, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Anebulo Pharma (ANEB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InterCure Ltd. (INCR)|NTRB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nasus Pharma NSRX|India Globalization Capital - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MIRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|FLGC: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMCC: EV/EBITDA Multiple|Company Value to EBITDA Adial Pharmaceuticals, Inc. (ADIL)|ARTL (Artelo Biosciences Inc.) - EV/EBITDA Multiple|ENSC - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple TTNP|Total Company Value to Operating Income Before Depreciation Ratio Greenlane Corp|InMed Pharmaceuticals - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple akandacorp.com AKAN|ENVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bright Green (BGXX) - Enterprise Value to EBITDA Ratio|HPCO (Hempacco) - Enterprise Value to EBITDA Ratio